Virtuozzo Acquires OnApp, Enabling More Comprehensive Intuitive Cloud Infrastructure Solutions for Service Providers
20.7.2021 11:00:00 EEST | Business Wire | Press release
Virtuozzo’s mission is to help shape the future of the cloud by empowering service providers with comprehensive, high performance, flexible and easy-to-use cloud infrastructure solutions supporting private, public and hybrid cloud use cases. To that end, Virtuozzo, a global leader in high-efficiency virtualization and hyperconverged software solutions, today announced it is acquiring OnApp, a London-based software company focused on cloud solutions for service providers. The acquisition augments Virtuozzo’s existing cloud IaaS and PaaS products while expanding its regional market reach.
Future-proofed Cloud Flexibility, Simplicity and Automation
The combined technological and R&D strengths of both companies directly target the evolving needs of Cloud Service Providers (CSPs), Managed Service Providers (MSPs), and Hosting Providers focused on providing IaaS, PaaS and XaaS solutions for their customers.
The resulting solution stack will pair Virtuozzo’s easy-to-use virtualization, containerization, storage and orchestration capabilities with advanced features of OnApp’s flexible self-service management platform. In turn, service providers will gain access to today’s most intuitive and robust cloud infrastructure and platform solutions capable of supporting any cloud use case.
“Virtuozzo’s primary expertise has traditionally been in high-density server virtualization and software-defined storage. We have successfully expanded over the last few years into hyperconverged infrastructure as it is crucial to the market’s evolution,” said Alex Fine, Virtuozzo CEO. “Simple, flexible and smart access to those strong, fundamental technologies is core to the success of MSPs, CSPs and Hosting Providers and therefore, core to ours. OnApp shares that commitment and brings to Virtuozzo incredible engineering talent and complementary technologies that help us advance the cloud infrastructure industry as a whole. We’re proud and excited to have the OnApp team on board.”
Market Growth Driving Innovation
Timing and demand are key factors behind the acquisition. Synergy Research Group recently reported that cloud infrastructure demand reached $129 billion in 2020, growing 35% year over year. About a third of this market is owned by non-hyperscalers—local, regional and multi-national service providers. Those providers are the beneficiaries of Virtuozzo technology.
In parallel, 451 Research, a part of S&P Global Market Intelligence, recently discussed in its 2021 analysis Demand and Opportunity in the Alternative Cloud Provider Market a potential new opportunity for alternative CSPs, noting that they may find a role in larger multi-cloud portfolios and that “alternative can mean ‘in addition to’ rather than ‘instead of.’”1 Collectively, these reports suggest that alternative CSPs and MSPs are well-positioned to become partners of choice for customers shifting to modern cloud services.
“In addition to OnApp technical expertise in cloud orchestration, user interface and content delivery networks, Virtuozzo sees the value our highly talented staff brings to the table,” stated Ditlev Bredahl, CEO, OnApp. “Integration and evolution of the joint solution stack will be strongly beneficial to the customers of both companies.”
Terms of the transaction were not disclosed. Per the agreement, OnApp will continue operation as a division of Virtuozzo with OnApp’s staff integrating into Virtuozzo’s organizational structure. Business will continue as usual with Bredahl assisting with post-acquisition integration.
About OnApp
OnApp provides software and services that enable hosts, MSPs and telecoms providers to create and sell their own public, private and hybrid clouds. OnApp launched in July 2010, and to date has deployed more than 6,000 clouds for service providers in 93 countries. OnApp has 130 staff across the EU, U.S. and Asia-Pacific and is headquartered in London, UK. For more information, visit https://onapp.com.
About Virtuozzo
Virtuozzo (www.virtuozzo.com) is a leading, global provider of hybrid virtualization, storage, and cloud enablement software solutions. The Company's software-defined, hyperconverged self-service platform and resource management capabilities enable hosting and service providers to provide end-customers with public and private cloud services. Virtuozzo is an industry pioneer who developed the first commercially available container technology 21 years ago. The Company provides software solutions and services to over 450 service providers, ISVs, and enterprises worldwide to enable over 500 thousand virtual environments, running mission-critical cloud workloads. A significant force in the open-source community, Virtuozzo sponsors and/or is a contributor to numerous open-source projects including KVM, Docker, OpenStack, OpenVZ, CRIU, and the Linux kernel.
1 Demand and Opportunity in the Alternative Cloud Provider Market, Liam Eagle, 451 Research, a part of S&P Global Market Intelligence. January 2021.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210720005004/en/
Contact information
Heather Ailara/Deb Brown
211 Communications
+1.973.567.6040
heather@211comms.com
/
deb@211comms.com
Christine Brunelli
Virtuozzo
+1 215-847-7842
christine.brunelli@virtuozzo.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom